Lilly exec says supply, reimbursement are factors for new Mounjaro launches

The top international executive at Eli Lilly on Tuesday said the pharmaceutical company will consider regulatory approvals, reimbursement and sufficient supplies before deciding whether to launch its weight-loss drug Mounjaro in new markets.

"My goal is to actually bring all of our therapies and innovation to as many markets as possible and expand access," Ilya Yuffa, president of Lilly International, told Reuters at the World Economic Forum (WEF) annual meeting. (Join GMF, a chat room hosted on LSEG Messenger, for live interviews: https://lseg.group/3TN7SHH) (Divya Chowdhury in Davos and Savio Shetty in Mumbai; Writing by Patrick Wingrove; Editing by Mark Porter)